Development of early dementia imaging marker by using a quantitative susceptibility mapping (QSM) and blood brain barrier (BBB) permeability imaging
- Conditions
- Mental and behavioural disorders
- Registration Number
- KCT0008510
- Lead Sponsor
- Konkuk University Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 75
Age 45 to 80 years old.
- Individuals who have agreed to participate in the clinical trial and voluntarily signed the written informed consent form.
- Patients who clinically correspond to the normal aging group or patients who meet the clinical diagnostic criteria for Mild Cognitive Impairment according to the 2011 NIA-AA (National Institute on Aging-Alzheimer's Association) guidelines.
- Primarily, patients who have undergone an amyloid PET scan, if possible, are the primary targets.
Exclusion criteria include individuals with a history of drug addiction, past or current neurological, psychiatric, neurosurgical diseases, or head trauma. Those who have taken psychiatric medications at doses higher than the therapeutic range that could affect brain waves in the past three months are also excluded. The study targets only individuals found to be free from dementia, based on a medical history survey, neurological examination, and cognitive function test conducted by a neurology specialist.
Study & Design
- Study Type
- Observational Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method susceptiblity (brain iron), BBB permeability
- Secondary Outcome Measures
Name Time Method Temporal changes in susceptibility (brain iron) and BBB permeability.